NMTR News and Press, 9 Meters Biopharma Inc. From 11/08/22

Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimen Clinical plans and activities are underway including site and patient recruitment to facilitat...

Preclinical data investigated the use of glucose-dependent insulinotropic polypeptide (GIP) monoclonal antibodies (mAbs) to prevent and treat obesity in animal models Poster granted Outstanding Research Award 9 Meters is developing NM-136, an anti-GIP humanized mAb, for targeted o...

RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual...

Clinical-stage company 9 Meters Biopharma ( NASDAQ: NMTR ) is set to execute a 1-for-20 reverse stock split, effective Oct. 17 5:00 p.m. ET. The company will begin trading on a split-adjusted basis from Oct. 18 under the existing ticker symbol NMTR. The move, whic...

RALEIGH, NC / ACCESSWIRE / October 17, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it will be executing a reverse stock split of its outstanding shares of com...

A North Carolina-based %Biotech company is seeing some premarket action on Tuesday after the company announced the final results from the Phase 2 VIBRANT study of vurolenatide in %ShortBowelSyndrome (SBS) and the outcome of its End-ofPhase 2 meeting with the FDA, according to the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a look at the biggest pre-market stock movers for Tuesday morning! Moving shares this morning is a reverse stock split, clinical trial re...

9 Meters Biopharma, Inc. ( NASDAQ: NMTR ), a company focused on rare digestive diseases, added ~24% pre-market Tuesday in reaction to final Phase 2 data for vurolenatide, a candidate for short bowel syndrome (SBS). A long-acting GLP-1 receptor agonist, vurolenatide, is d...

Vurolenatide 50 mg every two weeks (Q2W) dosing arm demonstrated a 30% reduction over six weeks in the primary endpoint of the Phase 2 study, mean reduction in total stool output (TSO), compared with a 32% increase for placebo - for a mean relative reduction of 62% Based on End-of-Phas...

RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will ...